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Abstract Missense mutations and intronic mutations in the tau
gene cause frontotemporal dementia and Parkinsonism linked to
chromosome 17 (FTDP-17). Known missense mutations reduce
the ability of tau to promote microtubule assembly. Intronic
mutations lead to increased mRNA splicing of the alternatively
spliced exon 10, resulting in an overproduction of tau isoforms
with four microtubule-binding repeats. We show here that the
recently identified FTDP-17 missense mutations N279K and
S305N do not reduce the ability of tau to promote microtubule
assembly. Instead they lead to increased splicing of exon 10, like
the intronic mutations. The N279K and S305N mutations define
a class of missense mutations in tau whose primary effects are at
the RNA level.
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1. Introduction
Mutations in the gene for microtubule-associated protein
tau cause familial frontotemporal dementia and Parkinsonism
linked to chromosome 17 (FTDP-17) [1^4]. Four missense
mutations and four intronic mutations have been identi¢ed
in approximately 20 FTDP-17 families. Neuropathologically,
all the FTDP-17 cases examined to date are characterised by
an abundant ¢lamentous tau pathology [5,6].
In adult human brain, six tau isoforms are produced from a
single gene by alternative mRNA splicing [7]. They di¡er by
the presence or absence of inserts of 29 and 58 amino acids
located in the amino-terminal half and a 31 amino acid repeat
located in the carboxy-terminal half. Inclusion of the latter,
which is encoded by exon 10 of the tau gene [7^9], gives rise to
tau isoforms with four microtubule-binding repeats.
Intronic mutations are located close to the splice-donor site
of the intron following exon 10, where they destabilise a pre-
dicted stem-loop structure [2,3]. They are found at positions
+3, +13, +14 and +16, with the ¢rst nucleotide of the splice-
donor site taken as +1. Intronic mutations have been shown
to lead to increased production of exon 10-containing tran-
scripts [2] and to increased levels of the three tau isoforms
with four microtubule-binding repeats [3]. Overproduction
of four-repeat tau isoforms may lead to an excess of tau
over available binding sites on microtubules [3], resulting in
the assembly of four-repeat tau isoforms into wide twisted
ribbons [10]. The known exonic mutations in tau are located
in the microtubule-binding repeat region or close to it [1,2,4].
They are G272V in exon 9, P301L in exon 10, V337M in exon
12 and R406W in exon 13 (using the numbering of the longest
human brain tau isoform). Mutations in exon 10 only a¡ect
four-repeat tau isoforms, whereas missense mutations located
outside exon 10 a¡ect all six tau isoforms [1,2,4].
We have previously shown that the four exonic mutations
all lead to a reduced ability of tau to promote microtubule
assembly, which was more marked for three-repeat than for
four-repeat isoforms [11]. The P301L mutation produced the
largest e¡ect, the R406W mutation the smallest e¡ect and the
G272V and V337M mutations intermediate reductions. A re-
duced ability of tau to interact with microtubules may be the
primary e¡ect of these missense mutations and may be neces-
sary for setting in motion the mechanisms that lead to the
assembly of tau into narrow twisted ribbons, as is the case
of mutations in exon 10 [12], or into paired helical and
straight ¢laments, as is the case of missense mutations located
outside exon 10 [13]. A subsequent study using only four-
repeat tau isoforms has also reported a reduced ability of
mutant recombinant tau to promote microtubule assembly
[14]. However, the relative e¡ects of the various mutations
were very di¡erent from those obtained in our study [11].
The reasons for these signi¢cant discrepancies remain to be
established.
Recently, two additional missense mutations in exon 10
have been identi¢ed in two FTDP-17 families [15,16]. The
N279K mutation (AAT to AAG) of pallido-ponto-nigral de-
generation (PPND) [15] creates a purine-rich stretch (AA-
GAAGAAG), which resembles an exon splice-enhancer con-
sensus sequence [17,18], suggesting that it may a¡ect splicing
in of exon 10 [15]. The S305N mutation (AGT to AAT) is
located in the last amino acid of exon 10 [16]. It forms part of
the predicted stem-loop structure at the exon 10-5P intron
boundary, where the G to A transition is found at position
31. As a result of this mutation, the predicted stem-loop is
destabilised, suggesting that it may also lead to increased
splicing of exon 10.
We have examined the e¡ects of the N279K and S305N
mutations on the splicing of exon 10 and the ability of tau
to promote microtubule assembly. We show here that, unlike
other missense mutations, the N279K and S305N mutations
produce no reductions in the ability of tau to promote micro-
tubule assembly. However, like the intronic mutations, they
lead to increased splicing of exon 10, demonstrating that their
primary e¡ects are at the RNA level.
2. Materials and methods
2.1. Production of tau proteins and microtubule assembly
Site-directed mutagenesis was used to change N279 to lysine and
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S305 to asparagine (using the numbering of the 441 amino acid iso-
form of human brain tau) in the four-repeat 412 amino acid isoform
(expressed from cDNA clone htau46). All constructs were veri¢ed by
DNA sequencing. The P301L htau46 construct has been described
[11]. Wild-type and mutated tau proteins were expressed in Escher-
ichia coli BL21(DE3), as described [19]. Recombinant tau proteins
were puri¢ed as described [11]. Tau protein concentrations were de-
termined using densitometry (Molecular Dynamics) and calibration
against tau protein of known concentration. Bovine serum albumin
was used as the standard for densitometry. In each experiment, wild-
type and mutant tau proteins were expressed and puri¢ed in parallel.
Puri¢ed recombinant wild-type and mutant htau46 proteins (0.1 mg/
ml, 2.3 WM) were incubated with bovine brain tubulin (1 mg/ml, 20
WM, cytoskeleton) in assembly bu¡er at 37‡C, as described [11]. The
assembly of tubulin was monitored over time by a change in turbidity
at 350 nm.
2.2. Exon trapping
The wild-type construct and constructs with the N279K mutation,
the P301L mutation, the S305N mutation and the +16 intronic muta-
tion were used. For making the wild-type construct, PCR products
were obtained from genomic DNA of a control individual. They in-
cluded the 93 nucleotides of exon 10, as well as 34 nucleotides at the
3P intron-exon 10 boundary and 85 nucleotides at the exon 10-5P
intron boundary, with SacI sites at each end. Site-directed mutagen-
esis was used to introduce the N279K, P301L and S305N missense
mutations in exon 10, as well as the +16 intronic mutation in the
intron following exon 10. All the constructs were veri¢ed by DNA
sequencing. PCR products were digested with SacI and subcloned into
the SstI site of the splicing vector pSPL3 (Life Technologies). For
exon trapping, COS7 cells were transiently transfected with 5 Wg/ml
plasmid DNA using DEAE-dextran/chloroquine. Cells were harvested
24 h later and RNA extracted using the Trizol reagent (Life Technol-
ogies). First-strand cDNA synthesis and PCR were done using a
commercially available system (Life Technologies), following the man-
ufacturer’s instructions. The nested PCR reactions used 30 cycles (de-
naturation 95‡C, 1.5 min; annealing 60‡C, 1.5 min; extension 72‡C,
2.5 min). The proportion of exon 10-containing transcripts was deter-
mined by image analysis of photographs of ethidium bromide-stained
agarose gels of the PCR products. Various amounts of the primary
PCR reactions and di¡erent numbers of ampli¢cation cycles were
used in control experiments, to ensure that the PCR reactions were
quantitative. In each experiment, all ¢ve constructs were run in paral-
lel. The identities of the PCR products were veri¢ed by DNA sequenc-
ing.
3. Results
Recombinant htau46 proteins with the N279K or S305N
mutation in exon 10 (Fig. 1) were expressed and their ability
to promote microtubule assembly examined. When compared
with wild-type htau46, N279K htau46 had a similar ability to
promote microtubule assembly (Fig. 2). S305N htau46
showed a slightly increased ability to promote microtubule
assembly, when compared with wild-type protein; the increase
was approximately 15%, when expressed as the optical density
at 2 min (Fig. 2). These ¢ndings contrast with those obtained
with P301L htau46, which showed a greatly reduced ability to
promote microtubule assembly, in con¢rmation of our pre-
vious ¢ndings (Fig. 2) [11].
Exon trapping was used to investigate the e¡ects of the
N279K and S305N mutations on the splicing of exon 10-con-
taining transcripts, with the P301L mutation and the +16
intronic mutation being used as controls. The results were
expressed as the ratios of exon 10-containing over exon 10-
lacking transcripts (Fig. 3). The P301L mutation produced no
change, whereas the +16 intronic mutation produced an ap-
proximately 11-fold increase in the ratio of exon 10-contain-
ing over exon 10-lacking transcripts, in con¢rmation of a
previous study (Fig. 3) [2]. Both the N279K and S305N mu-
tations produced large increases in the splicing in of exon 10
(Fig. 3).
A 18-fold increase in the ratio of exon 10-containing over
exon 10-lacking transcripts was observed for the N279K mu-
tation and a 26-fold increase for the S305N mutation (Fig. 3).
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Fig. 1. The N279K and S305N mutations of the tau gene in FTDP-17. a: Schematic diagram of the six tau isoforms (A^F) that are expressed
in adult human brain. Alternatively spliced exons 2, 3 and 10 are shown in white. The N279K and S305N mutations in the alternatively spliced
exon 10 are indicated. They only a¡ect tau isoforms with four microtubule-binding repeats (D^F) (the repeats are shown as black bars). b: Nu-
cleotide sequence of the exon 10-intron junctions. c: Structure of the predicted stem-loop in the pre-mRNA of tau. Exon sequences are shown
in capital letters and intron sequences in small letters. The N279K and S305N mutations are indicated in panel b and the G to A transition of
the S305N mutation in panel c.
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4. Discussion
Missense mutations and intronic mutations in the tau gene
have recently been identi¢ed as the genetic lesions responsible
for familial FTDP-17 [1^4]. All the FTDP-17 cases examined
to date share an abundant ¢lamentous tau pathology, with
characteristic tau isoform patterns and ¢lament morphologies
[5,6,20]. Functionally, mutations studied so far fall into two
distinct groups. Missense mutations have been shown to pro-
duce a reduced ability of tau to interact with microtubules
[11]. This contrasts with the intronic mutations, which lead
to increased splicing in of exon 10 [2], resulting in a net over-
production of soluble tau isoforms with four microtubule-
binding repeats [3].
Here we describe the functional e¡ects of the N279K and
S305N mutations in exon 10. The N279K mutation had no
signi¢cant e¡ect on the ability of four-repeat tau to promote
microtubule assembly, in agreement with a recent report [14].
This contrasts with four-repeat tau with the S305N mutation
which had a slightly increased ability to promote microtubule
assembly. It represents the ¢rst example of a FTDP-17 muta-
tion that produces an increased ability of tau to interact with
microtubules. It remains to be seen whether this functional
e¡ect contributes to the pathogenesis of FTDP-17 in this fam-
ily. These ¢ndings indicate that the primary e¡ects of the
N279K and S305N mutations di¡er from those of the
G272V, P301L, V337M and R406W missense mutations,
which produce a reduced ability of tau to promote microtu-
bule assembly [11].
It has been suggested that the N279K mutation may lead to
increased splicing of exon 10, as it produces a purine-rich
stretch [15], which resembles a splice-enhancer consensus se-
quence [17,18]. We have therefore used exon trapping to in-
vestigate the e¡ects of the N279K mutation on the splicing of
exon 10. A large increase in exon 10-containing transcripts
was observed, demonstrating that the primary e¡ect of this
missense mutation is at the RNA level. The S305N mutation
changes the last amino acid of exon 10 and destabilises the
predicted stem-loop at the exon 10-5P intron boundary [16].
By exon trapping, it was found to produce a large increase in
the splicing in of exon 10, demonstrating that its primary
e¡ect is also at the RNA level.
The locations of tau mutations and their primary e¡ects
appear to determine the ¢lamentous and cellular pathologies
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Fig. 3. Exon trapping analysis of the e¡ects of the N279K, P301L
and S305N missense mutations and of the +16 intronic mutation on
the splicing of exon 10 of the tau gene. A: Ethidium bromide-
stained agarose gel of nested PCR products. The 270 bp band con-
tains exon 10, whereas the 177 bp band lacks exon 10. A single ex-
periment is shown. Similar results were obtained in three separate
transfection experiments. B: Quantitative analysis of exon trapping
of wild-type construct and constructs with the N279K, P301L,
S305N missense mutations and the +16 intronic mutation. The re-
sults are expressed as means þ S.D. (n = 3) of the ratios of exon 10-
containing (+Exon 10) over exon 10-lacking (3Exon 10) transcripts.
Fig. 2. E¡ects of the N279K, P301L and S305N mutations on the
ability of four-repeat htau46 (412 amino acid isoform of human
tau) to promote microtubule assembly. A: Polymerisation of tubulin
induced by wild-type htau46, htau46 N279K, htau46 P301L and
htau46 S305N, as monitored over time by turbidimetry. A typical
experiment is shown; similar results were obtained in three separate
experiments. B: Optical densities for wild-type htau46 and the three
tau mutants at 2 min (expressed as % of wild-type htau46, taken as
100%). The results are expressed as means þ S.D. (n = 3). Amino
acid numbering is according to the 441 amino acid isoform of hu-
man tau.
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of FTDP-17 [6,21]. Thus, missense mutations in exon 10,
which produce a reduced ability of tau to promote microtu-
bule assembly [1,2,4,11,14], lead to the formation of narrow,
twisted ribbon-like ¢laments that consist predominantly of
four-repeat tau isoforms [12]. The tau pathology is neuronal
and glial. Intronic mutations lead to an overproduction of
soluble four-repeat tau isoforms [2,3] and the assembly of
four-repeat tau into wide twisted ribbons [10]. The tau path-
ology is neuronal and glial, with a more extensive glial path-
ology than in cases with an exon 10 missense mutation that
results in a reduced ability of tau to interact with microtubules
[6,11,12]. Missense mutations located outside exon 10 lead to
the formation of paired helical and straight ¢laments which
are made of all six tau isoforms [1,13], like those from Alz-
heimer’s disease brain [22].
The N279K mutation is a missense mutation in exon 10
which leads to increased splicing in of exon 10. It is therefore
expected to lead to an overproduction of soluble four-repeat
tau isoforms and the formation of wide twisted ribbons made
of four-repeat tau, as in the FTDP-17 cases with intronic
mutations [3,10]. It is also expected to lead to a neuronal
and glial tau pathology, with an extensive glial component.
The known characteristics of the tau pathology of PPND, a
FTDP-17 with the N279K mutation, are entirely consistent
with these expectations [14,15,23]. The S305N mutation in
tau is predicted to lead to an overproduction of four-repeat
tau isoforms, followed by their assembly into wide twisted
ribbon-like ¢laments, as in the FTDP-17 cases with the
N279K mutation and the intronic mutations [3,10,14,23].
These studies must await the availability of suitable brain
tissue. Like the N279K mutation, the S305N mutation has
been shown to lead to a neuronal and glial tau pathology,
with an abundant glial component [16].
In conclusion, we have shown that the primary e¡ects of
two missense mutations located in exon 10 of the tau gene are
at the RNA level. Functionally, the N279K and S305N mu-
tations behave like the known intronic mutations, which also
produce large increases in exon 10-containing transcripts.
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